Bio-Rad Laboratories (BIO) Financials: History & Chart

Bio-Rad Laboratories, Inc.(BIO)

Medical - Devices · Hercules, CA

$380.12-5.99 (-1.55%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA

7,450 employees

www.bio-rad.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Norman D. Schwartz

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	2.59B	651.00M	592.10M	693.20M	653.00M	651.60M	585.40M	667.48M	649.73M
Cost of Goods Sold	1.25B	305.20M	282.70M	348.00M	309.60M	306.30M	279.40M	325.56M	293.83M
Gross Profit	1.34B	345.80M	309.40M	345.20M	343.40M	345.30M	306.00M	341.91M	355.90M
Gross Profit Margin	51.9%	53.1%	52.3%	49.8%	52.6%	53.0%	52.3%	51.2%	54.8%
Total Operating Expenses	1.11B	273.20M	275.30M	282.30M	278.10M	268.20M	282.30M	283.58M	291.44M
Research & Development	261.10M	61.20M	62.90M	65.70M	71.30M	60.50M	73.50M	79.62M	91.00M
Selling, General & Administrative	847.80M	212.00M	212.40M	216.60M	206.80M	207.70M	208.80M	204.00M	200.44M
Operating Income (EBIT)	235.00M	72.60M	34.10M	61.90M	66.40M	77.10M	23.70M	58.33M	64.47M
Operating Margin	9.1%	11.2%	5.8%	8.9%	10.2%	11.8%	4.0%	8.7%	9.9%
Income Before Tax (EBT)	350.40M	542.10M	-689.80M	929.20M	-431.10M	414.00M	83.40M	-908.90M	861.62M
Interest Income	88.00M	22.30M	21.00M	31.00M	13.70M	14.70M	36.20M	15.90M	15.50M
Interest Expense	36.70M	N/A	12.30M	12.10M	12.30M	12.60M	12.00M	12.19M	12.17M
Other Income/Expense	115.40M	469.50M	-723.90M	867.30M	-497.50M	336.90M	59.70M	-967.23M	797.15M
Net Income	222.40M	371.40M	-527.10M	720.00M	-341.90M	317.80M	64.00M	-715.80M	653.17M
Income Tax Expense	128.00M	170.70M	-162.70M	209.20M	-89.20M	96.20M	19.40M	-193.10M	208.45M
Net Profit Margin	8.6%	57.1%	-89.0%	103.9%	-52.4%	48.8%	10.9%	-107.2%	100.5%
EBITDA	382.50M	72.60M	75.00M	114.30M	120.60M	127.70M	61.80M	107.63M	113.57M
EBITDA Margin	14.8%	11.2%	12.7%	16.5%	18.5%	19.6%	10.6%	16.1%	17.5%
Depreciation & Amortization	147.50M	0.00	40.90M	52.40M	54.20M	50.60M	38.10M	49.30M	49.10M
EPS Basic	8.33	13.89	-19.55	26.69	-12.70	11.67	2.29	-25.57	23.37
EPS Diluted	8.25	13.85	-19.55	26.65	-12.70	11.67	2.29	-25.57	23.34
Shares Outstanding	26.75M	26.75M	26.96M	26.98M	26.92M	27.23M	27.94M	28.00M	27.95M
Diluted Shares Outstanding	26.81M	26.81M	26.96M	27.01M	26.92M	27.23M	27.95M	28.00M	27.98M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.58B	2.57B	2.67B	2.80B	2.92B	2.55B	2.31B	2.29B
Cost of Goods Sold	1.24B	1.19B	1.24B	1.23B	1.28B	1.11B	1.05B	1.07B
Gross Profit	1.34B	1.38B	1.43B	1.57B	1.64B	1.44B	1.26B	1.22B
Gross Profit Margin	52.0%	53.7%	53.4%	55.9%	56.1%	56.5%	54.4%	53.5%
Total Operating Expenses	1.08B	1.11B	1.09B	1.08B	1.14B	1.02B	1.03B	1.03B
Research & Development	256.90M	295.90M	247.43M	256.89M	260.64M	217.76M	202.71M	199.20M
Selling, General & Administrative	819.90M	814.00M	841.70M	827.83M	877.12M	798.80M	824.63M	833.29M
Operating Income (EBIT)	270.50M	269.00M	337.80M	482.62M	500.34M	421.33M	229.66M	-108.64M
Operating Margin	10.5%	10.5%	12.6%	17.2%	17.1%	16.6%	9.9%	-4.7%
Income Before Tax (EBT)	995.50M	-2.34B	-850.10M	-4.70B	5.45B	4.92B	2.26B	507.36M
Interest Income	95.50M	82.00M	100.90M	58.00M	18.90M	18.20M	30.50M	26.60M
Interest Expense	49.00M	48.90M	49.44M	38.11M	1.55M	21.86M	23.42M	23.96M
Other Income/Expense	725.00M	-2.61B	-1.19B	-5.19B	4.95B	4.50B	2.03B	319.39M
Net Income	759.90M	-1.84B	-637.32M	-3.63B	4.25B	3.81B	1.76B	361.00M
Income Tax Expense	235.60M	-498.30M	-212.78M	-1.08B	1.19B	1.10B	502.41M	146.36M
Net Profit Margin	29.4%	-71.9%	-23.9%	-129.5%	145.6%	149.8%	76.1%	15.8%
EBITDA	475.90M	420.60M	483.70M	659.82M	637.94M	559.93M	404.16M	29.46M
EBITDA Margin	18.4%	16.4%	18.1%	23.5%	21.8%	22.0%	17.5%	1.3%
Depreciation & Amortization	205.40M	151.60M	145.90M	177.20M	137.60M	138.60M	174.50M	138.10M
EPS Basic	27.87	-65.36	-21.82	-121.79	142.61	127.86	58.93	12.10
EPS Diluted	27.87	-65.36	-21.82	-121.79	140.83	126.20	58.27	11.94
Shares Outstanding	27.26M	28.21M	29.21M	29.79M	29.83M	29.77M	29.84M	29.84M
Diluted Shares Outstanding	27.28M	28.21M	29.21M	29.79M	30.21M	30.16M	30.18M	30.23M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.